Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.

Abstract

Renal medullary carcinoma (RMC) is a rare and aggressive malignancy seen primarily in patients with sickle-cell trait. We report a complete response to carboplatin, paclitaxel, and gemcitabine in a patient with advanced metastatic RMC.

• Authors: Alexandra Walsh, David R Kelly, Yoginder N Vaid, Lee M Hilliard, Gregory K Friedman
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 55 Issue 6 Pg. 1217-20 (Dec 01 2010) ISSN: 1545-5017 [Electronic] United States
• PMID: 20979179 (Publication Type: Case Reports, Journal Article)

Chemical References

• Deoxycytidine
• Carboplatin
• Paclitaxel
• Gemcitabine

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (administration & dosage)
• Carcinoma, Renal Cell (drug therapy, secondary)
• Child
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Humans
• Kidney Neoplasms (drug therapy, secondary)
• Male
• Paclitaxel (administration & dosage)
• Sickle Cell Trait (drug therapy, pathology)
• Treatment Outcome
• Gemcitabine